Mirtogenol® and Glaucoma

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447819/

Results

After two months of supplementation with Mirtogenol®, the mean IOP decreased from a baseline of 25.2 mmHg to 22.2 mmHg. Nineteen of the twenty patients taking Mirtogenol had a decreased IOP after three months. No side effects were observed. Ocular blood flow improved.
Conclusions
The results of this study indicate that Mirtogenol® may represent a safe preventative intervention for lowering the risk for developing symptomatic glaucoma by controlling IOP and improving ocular blood flow.

Comments

Popular posts from this blog

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS

RINSING YOUR CONTACT LENS CASE IS NOT ENOUGH